PD1 Blocking Mouse Monoclonal Antibody [3A11] (EM1701-17)

UNIPROT #

Q15116

PROTEIN NAME

PD1 Blocking

SYNONYMS

CD279 antibody;CD279 antigen antibody;hPD 1 antibody;hPD l antibody;hPD-1 antibody;hSLE1 antibody;PD 1 antibody;PD-1 antibody;PD1 antibody;PDCD 1 antibody;PDCD1 antibody;PDCD1_HUMAN antibody;Programmed cell death 1 antibody;Programmed cell death 1 protein antibody;Programmed cell death protein 1 antibody;Protein PD 1 antibody;Protein PD-1 antibody;SLEB2 antibody;Systemic lupus erythematosus susceptibility 2 antibody

DEVELOPMENTAL STAGE

Induced at programmed cell death.

POST-TRANSLATIONAL MODIFICATION

Ubiquitinated at Lys-233 by the SCF(FBXO38) complex, leading to its proteasomal degradation. Ubiquitinated via 'Lys-48'-linked polyubiquitin chains.; Tyrosine phosphorylated at Tyr-223 (within ITIM motif) and Tyr-248 (ITSM motif) upon ligand binding. Phosphorylation at Tyr-248 promotes the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta.; N-glycosylation at Asn-58 consists of two N-acetylglucosamine units and one fucose. N-glycosylation does not affect binding to nivolumab drug.

SUBCELLULAR LOCATION

Membrane.

FUNCTION

PD-1 blockade works during the effector phase to restore the immune function of T cells in the periphery that have been turned off following extended or high levels of antigen exposure, as in advanced cancer. The ligands for PD-1 can be expressed by tumor cells as well as tumor-infiltrating immune cells. PD-L1 expression on tumor cells varies by tumor type and also within a given tumor type, but appears to be particularly abundant in melanoma, non–small cell lung cancer (NSCLC), and ovarian cancer. In a recent study, PD-L1 expression on tumor cells was shown to be significantly associated with PD-1 expression on TILs, and was locally associated with PD-L2 expression when this ligand was also expressed. In the same study, tumor PD-L1 expression was the single factor most closely correlated with response to anti-PD-1 blockade, whereas PD-L1 expression on TILs was not associated with response. patient response to anti-PD-L1 blockade was strongest when PD-L1 was expressed by tumor-infiltrating immune cells. This antibody recognizing the PD-L1 binding region of PD1.